Anti-NMDA Receptor Encephalitis

Anti-NMDA Receptor Encephalitis

Overview

Anti-NMDA Receptor Encephalitis (NMDARE) is the most common form of autoimmune encephalitis, characterized by antibodies targeting the GluN1 (NR1) subunit of the [NMDA receptor](/entities/nmda-receptor) in the brain[@dalmau2007]. First described in 2007 by Dalmau and colleagues as a paraneoplastic disorder associated with ovarian teratomas, NMDARE has emerged as a treatable cause of subacute encephalitis affecting individuals of all ages, with a predominance in young women[@dalmau2007][@hughes2010].

The condition accounts for approximately 1-2 per 100,000 annual encephalitis cases and represents a paradigmatic example of antibody-mediated synaptic dysfunction[@granerod2010][@graus2016]. Unlike neurodegenerative diseases where neuronal loss is irreversible, NMDARE is characterized by reversible receptor internalization, explaining why aggressive immunotherapy can yield substantial recovery even in severe cases[@titulaer2013].

Molecular Mechanism of Antibody Binding {#molecular-mechanism}

GluN1 Subunit Targeting

The pathogenic autoantibodies in NMDARE are predominantly IgG1 subclass antibodies that target the N-terminal domain (ATD) of the GluN1 (GRIN1) subunit of the [NMDA receptor](/entities/nmda-receptor)[@hughes2010]. Epitope mapping studies have identified the major binding site within amino acids 371-593 of the GluN1 extracellular domain, a region critical for receptor assembly and ligand binding[@chen2020].

Anti-NMDA Receptor Encephalitis

Overview

Anti-NMDA Receptor Encephalitis (NMDARE) is the most common form of autoimmune encephalitis, characterized by antibodies targeting the GluN1 (NR1) subunit of the [NMDA receptor](/entities/nmda-receptor) in the brain[@dalmau2007]. First described in 2007 by Dalmau and colleagues as a paraneoplastic disorder associated with ovarian teratomas, NMDARE has emerged as a treatable cause of subacute encephalitis affecting individuals of all ages, with a predominance in young women[@dalmau2007][@hughes2010].

The condition accounts for approximately 1-2 per 100,000 annual encephalitis cases and represents a paradigmatic example of antibody-mediated synaptic dysfunction[@granerod2010][@graus2016]. Unlike neurodegenerative diseases where neuronal loss is irreversible, NMDARE is characterized by reversible receptor internalization, explaining why aggressive immunotherapy can yield substantial recovery even in severe cases[@titulaer2013].

Molecular Mechanism of Antibody Binding {#molecular-mechanism}

GluN1 Subunit Targeting

The pathogenic autoantibodies in NMDARE are predominantly IgG1 subclass antibodies that target the N-terminal domain (ATD) of the GluN1 (GRIN1) subunit of the [NMDA receptor](/entities/nmda-receptor)[@hughes2010]. Epitope mapping studies have identified the major binding site within amino acids 371-593 of the GluN1 extracellular domain, a region critical for receptor assembly and ligand binding[@chen2020].

The antibodies recognize a conformational epitope that requires proper receptor tetramerization — isolated GluN1 subunits are not recognized, explaining why antibody binding requires intact surface receptors[@hughes2010]. This has therapeutic implications: antibodies can be displaced by competitive agonists (ifenprodil, D-serine) that bind nearby sites, providing rationale for pharmacologic intervention strategies[@chen2020].

Receptor Internalization Dynamics

Antibody binding triggers rapid, clathrin-dependent internalization of surface [NMDA receptors](/entities/nmda-receptor) through a process called capped-dependent endocytosis[@hughes2010][@chen2020]. Key kinetic features include:

• Rapid onset: Receptor density on neuronal surfaces decreases by 40-60% within 2 hours of antibody exposure[@chen2020]
• Subunit specificity: Only GluN1-containing receptors are affected; GluN1/GluN2B heteromers are preferentially lost over GluN1/GluN2A[@chen2020]
• Recovery timecourse: Receptor density returns to baseline within 24-48 hours after antibody removal in vitro, consistent with the clinical observation that early treatment leads to faster recovery[@hughes2010]
• Functional consequences: The loss of surface NMDARs reduces synaptic NMDAR-mediated currents, impairing calcium influx and downstream signaling cascades essential for synaptic plasticity[@badran2022]

Synaptic Plasticity Disruption

The loss of surface [NMDA receptors](/entities/nmda-receptor) has profound effects on glutamatergic signaling and synaptic plasticity[@badran2022][@lee2019]:

Hippocampal Neuronal Dysfunction {#hippocampal-dysfunction}

Memory Circuit Impairment

The hippocampus is particularly vulnerable in NMDARE due to its high density of [NMDA receptors](/entities/nmda-receptor) and critical role in declarative memory formation[@lee2019]. Functional MRI studies in NMDARE patients demonstrate:

• Reduced hippocampal activation during memory encoding tasks, correlating with anterograde amnesia severity[@lee2019]
• Disrupted default mode network connectivity, with reduced coupling between hippocampus and posterior cingulate cortex — a circuit critical for memory consolidation[@lee2019]
• Hyperactivation of prefrontal regions, suggesting compensatory mechanisms that fail to overcome hippocampal dysfunction[@lee2019]

Cellular Mechanisms

At the cellular level, hippocampal dysfunction in NMDARE involves[@badran2022][@lee2019]:

• CA1 pyramidal neuron hyperexcitability: Paradoxical increase in firing rates due to disinhibition when NMDAR-mediated excitation is reduced
• Inhibitory interneuron vulnerability: Interneurons expressing parvalbumin may be particularly affected, contributing to circuit-level dysfunction
• Astrocyte reactivity: Astrocyte-mediated glutamate reuptake is impaired, contributing to excitotoxic stress[@malter2023]
• Microglial activation: Microglia activation in the hippocampus correlates with cognitive impairment severity[@malter2023]

Neurocircuit-Level Effects

The antibody-mediated receptor loss propagates through memory circuits[@lee2019][@malter2023]:

CSF Cytokine and Biomarker Profile {#csf-biomarkers}

Inflammatory Profile

Cerebrospinal fluid analysis in NMDARE reveals a characteristic inflammatory signature[@blumen2022][@byrne2019]:

| Biomarker | Elevation | Clinical Significance |
|-----------|-----------|----------------------|
| CXCL13 | Elevated (2-100x controls) | B-cell recruitment; diagnostic sensitivity 80%[@day2023] |
| IL-6 | Elevated (median 15 pg/mL) | Correlates with disease severity and CSF pleocytosis[@byrne2019] |
| TNF-alpha | Mildly elevated | Associated with blood-brain barrier dysfunction[@byrne2019] |
| Neurofilament light chain (NfL) | Elevated in severe cases | Marker of neuronal injury; prognostic indicator[@vande2020] |
| GFAP | Variable | Astrocyte activation marker; returns to normal with recovery[@blumen2022] |
| Oligoclonal bands | Positive in 60-70% | Indicates intrathecal IgG synthesis[@blumen2022] |

CXCL13 as a Diagnostic Biomarker

CXCL13, a B-cell chemokine, has emerged as a highly specific biomarker for NMDARE[@day2023][@byrne2019]:

• Sensitivity: 77-84% in CSF (higher than serum alone)
• Specificity: 95% for distinguishing NMDARE from other encephalitides
• Prognostic value: Higher baseline CXCL13 correlates with longer time to functional recovery
• Dynamic changes: CXCL13 levels decline faster with effective immunotherapy, providing a biomarker for treatment response[@day2023]

Blood-Brain Barrier Involvement

Studies using dynamic contrast-enhanced MRI demonstrate that BBB disruption in NMDARE is not uniform[@byrne2019][@malter2023]:

• Temporal lobe predilection: Hippocampus and amygdala show greater BBB leakage
• Correlation with clinical features: More severe BBB disruption correlates with worse initial mRS scores
• Recovery: BBB integrity improves with successful immunotherapy, paralleling clinical recovery

Neuroinflammatory Imaging Correlates

PET studies using translocator protein (TSPO) ligands reveal widespread microglial activation in NMDARE[@malter2023]:

• Temporal lobes: Most affected, correlating with memory deficits
• Frontal cortex: Associated with psychiatric symptoms
• Cerebellum: Correlates with ataxia and movement disorder severity
• Recovery pattern: Microglial activation decreases with treatment, providing an objective marker of neuroinflammation resolution[@malter2023]

Clinical Features

Prodrome Phase

Many patients experience a prodromal phase lasting days to weeks[@dalmau2007][@graus2016]:

• Headache and low-grade fever (viral-like)
• Fatigue and malaise
• Upper respiratory symptoms
• Nausea and gastrointestinal disturbance

Core Neurological Syndrome

Psychiatric Manifestations

• Acute psychosis with hallucinations and delusions[@dalmau2007]
• Agitation and aggressive behavior
• Anxiety and panic attacks
• Mood disturbances (depression, mania)
• Catatonia (present in up to 25% of cases)

Seizures

• Generalized tonic-clonic seizures (most common)
• Focal seizures with impaired awareness
• Status epilepticus (in 30-50% of severe cases)[@escudero2017]
• Non-convulsive status epilepticus (frequently missed without continuous EEG monitoring)[@escudero2017]

Movement Disorders

• Orofacial dyskinesias (characteristic)[@dalmau2007]
• Limb dystonia and rigidity
• Choreoathetosis
• Myoclonus and tremor
• Pisa syndrome (axial dystonia)

Autonomic Dysfunction

• Tachycardia and hypertension
• Hyperthermia and temperature instability
• Hypoventilation (often requiring ICU admission)
• Urinary incontinence
• Cardiac arrhythmias (potentially life-threatening)

Disease Course

The classic progression of NMDARE follows distinct phases[@dalmau2007][@titulaer2013]:

Diagnosis

Graus Diagnostic Criteria

The 2016 Graus criteria provide structured diagnostic guidance[@graus2016]:

Antibody Testing

• CSF testing is preferred: Higher sensitivity (100% specificity) compared to serum alone[@graus2016]
• Cell-based assays (CBA): Gold standard for surface antibody detection
• Tissue-based testing: Indirect immunofluorescence on rodent brain tissue as complementary method
• Antibody titers: Quantified titers have prognostic value; higher titers correlate with worse outcomes and longer recovery[@titulaer2013]

Neuroimaging

MRI Brain

• Normal in up to 50% of cases, especially early in disease[@escudero2017]
• T2/FLAIR hyperintensities in[@dalmau2007]:
• Medial temporal lobes
• Frontal cortex
• Basal ganglia
• Cerebellum
• Brainstem
• May show hippocampal swelling and diffusion restriction in acute phase

FDG-PET

• More sensitive than MRI for detecting metabolic abnormalities[@escudero2017]
• Often shows hypermetabolism in basal ganglia and cerebellum in acute phase
• Hypometabolism in temporal lobes may persist into recovery phase

Electroencephalography

• Abnormal in >90% of patients[@escudero2017]
• Generalized or focal slowing (70%)
• Epileptiform discharges (40%)
• Extreme delta brush pattern: Characteristic but present in only 10-15% of cases — highly specific[@escudero2017]
• Continuous EEG monitoring essential given high frequency of non-convulsive status epilepticus[@escudero2017]

Immunotherapy and Treatment Response {#immunotherapy-response}

First-Line Immunotherapy

First-line immunotherapy produces clinical improvement in approximately 80-90% of patients when initiated promptly[@titulaer2013][@iranirad2023]:

| Treatment | Protocol | Response Rate | Time to Improvement |
|-----------|----------|---------------|-------------------|
| Corticosteroids (methylprednisolone) | 1g IV daily x 3-5 days, then oral taper | 65-75% improvement | 1-2 weeks[@titulaer2013] |
| IV Immunoglobulin (IVIG) | 0.4 g/kg/day x 5 days | 60-70% improvement | 1-2 weeks[@iranirad2023] |
| Plasma Exchange | 5-7 exchanges over 10-14 days | 70-80% improvement | Days to 1 week[@titulaer2013] |
| Combination therapy | Steroids + IVIG or PLEX | 85-90% improvement | 1-2 weeks[@iranirad2023] |

The combination of corticosteroids plus IVIG or plasma exchange is associated with faster recovery and higher response rates than monotherapy[@titulaer2013][@iranirad2023].

Tumor Removal

In the 30-50% of patients with associated ovarian teratomas, tumor resection significantly improves outcomes[@dalmau2007][@titulaer2013]:

• Odds ratio for good outcome with tumor removal: 2.4 (95% CI 1.2-4.6)
• Tumor removal often accelerates immunotherapy response
• Follow-up tumor screening recommended even if initial imaging negative

Second-Line Immunotherapy

For patients with inadequate response to first-line therapy (approximately 20-25%)[@titulaer2013][@heeke2021]:

| Agent | Mechanism | Response Rate | Indications |
|-------|-----------|---------------|-------------|
| Rituximab (anti-CD20) | B-cell depletion | 70-80% improvement | Refractory symptoms after 2-4 weeks of first-line |
| Cyclophosphamide | Broad immunosuppression | 60-70% improvement | Severe refractory cases |
| Azathioprine/Mycophenolate | Maintenance therapy | Adjunctive benefit | Long-term relapse prevention |

Rituximab significantly reduces relapse rates from 15-20% to <5% and is increasingly used earlier in treatment protocols[@titulaer2013][@heeke2021].

Long-Term Outcomes and Relapse

Long-term follow-up studies demonstrate[@heeke2021][@titulaer2013]:

• 75-80% achieve good functional recovery (mRS 0-2) at 2 years
• Cognitive deficits persist in 20-30%, particularly affecting memory and executive function
• Relapse rate: 10-20% within first 2 years, reduced to <5% with rituximab maintenance
• Residual epilepsy: 10-15% develop chronic epilepsy
• Quality of life: 60-70% return to baseline functional status at 5 years

Comparison with Anti-LGI1 and Anti-GABABR Encephalitis {#subtype-comparison}

| Feature | Anti-NMDA Receptor | Anti-LGI1 | Anti-GABA_B Receptor |
|---------|-------------------|-----------|---------------------|
| Antibody target | GluN1 subunit of NMDA receptor | Leucine-rich glioma-inactivated 1 (LGI1) protein | GABA_B receptor subunits (GABA_B1/GABA_B2) |
| Primary antigen location | Synaptic NMDA receptor complex | Adhesion molecule linking presynaptic Kv1 to postsynaptic AMPAR | Postsynaptic GABA_B receptors |
| Age | Median 21 years; bimodal (young adults, older adults) | Median 64 years; predominantly older males | Median 55-65 years |
| Sex distribution | Female predominance (4:1) | Male predominance (2:1) | Male predominance (2:1) |
| Tumor association | Ovarian teratoma (30-50% of females); SCLC | Usually non-paraneoplastic | Small cell lung cancer (50-60%) |
| Classic presentation | Psychiatric symptoms, seizures, dyskinesias, dysautonomia | Faciobrachial dystonic seizures, limbic encephalitis | Limbic encephalitis, prominent seizures, ataxia |
| CSF pleocytosis | Common (60-80%) | Often normal | Common (60-70%) |
| MRI findings | Often normal; may show basal ganglia/temporal hyperintensities | Characteristic hippocampal T2/FLAIR hyperintensity | Temporal lobe abnormalities |
| First-line response | 80-90% improvement | 90-95% improvement | 75-85% improvement |
| Time to recovery | Weeks to months; can take 1-2 years | Often within weeks | Weeks to months |
| Cognitive outcomes | Variable; executive/memory deficits in 20-30% | Generally good; memory deficits may persist | Moderate; memory impairment common |
| Relapse rate | 10-20% (reduced to <5% with rituximab) | 10-15% | 10-20% |
| Mortality | 5-10% (higher if severe dysautonomia) | <2% | 10-15% (often related to underlying malignancy) |

Key Mechanistic Differences

Anti-NMDAR vs Anti-LGI1: The critical difference lies in pathogenic mechanism. Anti-NMDAR antibodies cause receptor internalization and functional loss of a major glutamate receptor subtype, disrupting synaptic plasticity broadly[@hughes2010][@chen2020]. Anti-LGI1 antibodies disrupt a synaptic adhesion complex without causing receptor internalization, explaining the predominantly limbic (memory) presentation and faster recovery[@nosadri2022].

Anti-NMDAR vs Anti-GABA_B R: Both target postsynaptic receptors with opposing effects on neuronal excitability. Anti-GABA_B R antibodies reduce inhibitory signaling, predisposing to severe seizures and status epilepticus. The paraneoplastic association with SCLC in anti-GABA_B R encephalitis also impacts prognosis through malignancy-related mortality[@nosadri2022].

Epidemiology

• Incidence: Approximately 1.5-2 per million per year[@granerod2010]
• Age: Affects all ages; median onset ~21 years[@dalmau2007]
• Sex: Strong female predominance (4:1 overall; >95% in teratoma-associated cases)[@dalmau2007]
• Associated tumors: 30-50% have underlying neoplasms (ovarian teratoma >> SCLC, other)[@dalmau2007][@titulaer2013]

Prognostic Factors

Favorable[@titulaer2013][@heeke2021]:

• Early treatment initiation (within 4 weeks)
• Tumor removal when present
• Less severe disease at presentation (mRS <3)
• Female sex
• Lower baseline antibody titers
• Absence of ICU admission

• Delayed treatment (>8 weeks from symptom onset)
• Refractory status epilepticus
• Severe dysautonomia requiring ICU
• High baseline antibody titers
• No tumor identified (may indicate more severe idiopathic form)
• Older age at onset

Relationship to Neurodegeneration

While primarily an autoimmune condition, NMDARE provides important mechanistic insights relevant to neurodegenerative diseases[@badran2022][@malter2023]:

See Also

• [/diseases/autoimmune-encephalitis](/diseases/autoimmune-encephalitis)
• [/diseases/limbic-encephalitis](/diseases/limbic-encephalitis)
• [/diseases/caspr2-encephalitis](/diseases/caspr2-encephalitis)
• [/entities/nmda-receptor](/entities/nmda-receptor)
• [/mechanisms/neuroinflammation](/mechanisms/neuroinflammation)
• [/mechanisms/excitotoxicity](/mechanisms/excitotoxicity)
• [/therapeutics/immunotherapy](/therapeutics/immunotherapy)

External Links

• [NINDS Anti-NMDA Receptor Encephalitis Information](https://www.ninds.nih.gov/Disorders/All-Disorders/Anti-NMDA-Receptor-Encephalitis-Information-Page)
• [Encephalitis Society - Anti-NMDA Receptor Encephalitis](https://www.encephalitis.info)
• [Autoimmune Encephalitis Alliance](https://aealliance.org)